Market Signal Briefing

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. ("IS&S" or the "Company") (NASDAQ: ISSC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  

The investigation concerns whether IS&S and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 14, 2025, IS&S issued a press release announcing its financial results for its fiscal third quarter of 2025.  Therein, the Company's Chief Executive Officer Shahram Askarpour advised, among other things, that a "pull-forward of F-16 production into the current quarter . . . will impact revenue over the next two quarters[.]" 

On this news, IS&S's stock price fell $6.22 per share, or 31.53%, to close at $13.51 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE: CTO) and certain officers. The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired CTO securities during the Class Period, you have until October 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

CTO is a publicly traded real estate investment trust ("REIT") that owns and operates a portfolio of purported high-quality, retail-based properties located primarily in higher growth markets in the United States ("U.S."). The Company converted into a REIT in February 2021 and, as of December 31, 2024, owned 23 income properties in seven states, including Ashford Lane, a retail and dining center in Atlanta, Georgia.

Under guidelines established by the U.S. Securities and Exchange Commission ("SEC"), REITs must pay out at least 90% of their taxable profits to shareholders annually as dividends. In return, REIT companies are exempt from most corporate income tax. CTO has touted that its operation as a REIT "provides the tax-efficient organizational structure for [its] stockholders" that "will allow [it] to provide them with an attractive and sustainable dividend."

To measure its performance, CTO uses the financial metric Adjusted Funds from Operations ("AFFO"). The AFFO of a REIT, though subject to varying methods of computation, is generally equal to the REIT's funds from operations with adjustments made for recurring capital expenditures (also referred to as "capex") used to maintain the quality of the REIT's underlying assets. Professional analysts tend to prefer AFFO because it takes into consideration additional costs incurred by the REIT as well as additional income sources, such as rent increases. Thus, analysts believe that AFFO provides for a more accurate base number when estimating present values and a better predictor of the REIT's future ability to pay dividends.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) CTO's dividends were less sustainable than Defendants had led investors to believe; (ii) the Company used deceptive and unsustainable practices to artificially inflate its AFFO and overstate the true profitability of its Ashford Lane property; (iii) accordingly, CTO's business and/or financial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On June 25, 2025, Wolfpack Research ("Wolfpack") published a report entitled "CTO: The B. Riley of REITs" (the "Wolfpack Report" or the "Report"), which compared CTO unfavorably to B. Riley, a financial services company that recently lost more than 90% of its value amid three years of losses, soured investments, delayed financial reports and revelations that the SEC had been investigating whether the firm gave shareholders an accurate picture of its health. Citing interviews with former employees and whistleblowers, the Wolfpack Report accused CTO of, among other things, "not generat[ing] enough cash to pay its recurring capex and cover its dividends since converting to a REIT in 2021" and instead "rel[ying] on dilution (increasing shares outstanding by 70% since December 2022) to cover a $38 million dividend shortfall from 2021 to 2024," employing a "manipulative definition of [AFFO] where they exclude recurring capex, unlike all of their self-identified shopping center REIT peers," and "us[ing] a sham loan to hide the collapse of a top tenant from shareholders at Ashford Lane." (Emphasis in original). Further, Wolfpack predicted imminent further dilution of the Company, noting that CTO has just $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million per quarter, along with approximately $12 million in additional planned capital expenditures.

On this news, CTO's stock price fell $0.98 per share, or 5.42%, to close at $17.10 per share on June 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. ("Coty" or the "Company") (NYSE: COTY).

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc.  ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  

[Click here for information about joining the class action]

  Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma. The Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells.  According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases."  In 2024, to "strengthen [its] balance sheet and support development of briquilimab," Jasper completed an oversubscribed $50 million financing "with a syndicate of leading life science investors," purportedly "extending [its] cash runway through the third quarter of 2025."

In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the "BEACON Study").  When announcing the first patient dosing in the BEACON Study, Jasper's Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was "confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases."  In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the "ETESIAN Study").  In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency ("SCID") patients undergoing a second stem cell transplant.

Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a "lot number."  Drug "lots" are batches of a product that are manufactured, processed, packaged, or stored under the same conditions.  If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers.

According to the Company, "[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices ("cGMP")] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control."  Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported "accordance with cGMP regulations for use in [its] clinical studies."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study.  The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing."  Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma."  Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses."

On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

Market analysts were quick to comment on the Company's announcement.  For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the "BMO Report").  The BMO Report stated, in relevant part, that "potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward" given, among other things, Jasper's "financing overhang" and market competition.

After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled "Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway."  The press release revealed that Jasper was reducing its workforce by approximately 50%, that "[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs," and that Defendant Edwin Tucker was departing his role as the Company's Chief Medical Officer effective August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lesaka Technologies, Inc. ("Lesaka" or the "Company") (NASDAQ: LSAK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Lesaka and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 10, 2025, Lesaka disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC") that the Audit Committee of its Board of Directors had "concluded that the Company's unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively, included in the Company's Quarterly Reports on Form 10-Q for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, respectively (the "Quarterly Reports"), should be restated, and that such unaudited condensed financial statements should no longer be relied upon, due to the Company's re-evaluation of the classification of certain revenue that has been reported as an agent rather than as principal, and related cost of goods sold." 

On this news, Lesaka's stock price fell $0.48 per share, or 10.15%, to close at $4.25 per share on September 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE: FCX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after "a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine," trapping seven workers. 

On this news, Freeport's stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until September 30, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Novo Nordisk securities during the Class Period. A copy of the Complaint can be obtained at  www.pomerantzlaw.com .

[Click here for information about joining the class action]

On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."

 On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired SelectQuote securities during the Class Period. A copy of the Complaint can be obtained at  www.pomerantzlaw.com .

[Click here for information about joining the class action]

On May 1, 2025, the U.S. Department of Justice ("DOJ") filed a False Claims Act complaint against SelectQuote, alleging "[f]rom 2016 through at least 2021" SelectQuote received "tens of millions of dollars" in "illegal kickbacks" from health insurance companies in exchange for steering Medicare beneficiaries to enroll in the insurers' plans. Further, according to the DOJ, SelectQuote, in exchange for kickbacks, engaged in a conspiracy with major insurers to illegally discriminate against beneficiaries deemed to be less profitable, including those with disabilities. The DOJ concluded that SelectQuote made materially false claims by stating it offers "unbiased coverage comparisons" when in fact it "repeatedly directed Medicare beneficiaries to the plans offered by insurers that paid them the most money, regardless of the quality or suitability of the insurers' plans." 

On this news, SelectQuote's stock price fell $0.61 per share, or 19.24%, to close at $2.56 per share on May 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Fly-E and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fly-E securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On August 14, 2025, Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues "primarily driven by a decrease in total units sold."  In pertinent part, the Company attributed the decline to "recent lithium-battery accidents involving E-Bikes and E-Scooters." 

On this news, Fly-E's stock price fell $6.76 per share, or 87.11%, to close at $1.00 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations.  Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged "temporal competitive disruption."  The Company further reduced its previous full-year projections due to Pylarify's shortfall. 

On this news, Lantheus's stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025. 

Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS") and revenue figures that missed expectations.  Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company's full-year 2025 projections.  Lantheus attributed its results in part to ongoing competition, which impacted Pylarify's pricing dynamics. 

On this news, Lantheus's stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25-cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Nutex securities during the Class Period, you have until October 21, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Nutex is a physician-led, healthcare services and operations company that began publicly trading via a reverse merger in April 2022. The Company operates through three divisions: a hospital division comprised of 24 hospital facilities in 11 states, a population health management division, and real estate. Nutex generally operates as an out-of-‎network provider and generates revenue, in part, from contracts with patients and, in most cases, a third-party payor such as commercial insurance, workers compensation insurance or, in limited cases, Medicare or Medicaid. According to Nutex, on average, greater than 90% of its net patient service revenue is paid by third-party payors.

Prior to 2022, if a patient with health insurance received care from an out-of-network provider, even unknowingly, the patient's health plan might not have covered the entire out-of-network cost, leaving the patient with higher costs than if the care had come from an in-network provider. In addition to any out-of-network cost sharing the patient might have owed, the out-of-network provider could bill the patient for the difference between the billed charge and the amount the patient's health plan paid, unless banned by state law—a practice called "balance billing". An unexpected balance bill from an out-of-network provider is frequently referred to as a "surprise bill".

In December 2020, to curb surprise out-of-network billing, Congress enacted the No Surprises Act ("NSA"). The NSA, which took effect January 1, 2022, requires private health plans to cover out-of-network claims and apply in-network cost sharing, and prohibits doctors, hospitals, and other covered providers from billing patients more than the in-network cost sharing amount for surprise medical bills. In addition, the NSA established an independent dispute resolution ("IDR") process to determine out-of-network payment amounts between health plans and providers when open negotiations fail to result in an agreed-upon payment amount.

In the IDR process, the provider and health plan each submit a proposed payment amount and ‎‎additional information supporting their payment offers to an arbitrator, a certified IDR entity. The arbitrator must select one of the two proposed payment amounts, taking into ‎account the ‎‎"qualifying payment amount" ("QPA")—the median contract rate for like specialties in the same geographical market—and additional circumstances including, among other things, the level of training, outcomes ‎‎measurements of the facility, the acuity of the individual treated, and the case mix and scope of services of the ‎facility ‎providing the service.

Initially, as an out-of-network provider, Nutex's business suffered after the NSA went into effect. Specifically, because cost sharing under the statute is generally based on the median in-network rate a health plan pays for a service, the NSA prevented Nutex from charging patients higher prices for its services through out-of-network billing. Indeed, in March 2023, Nutex reported that "[s]ince the NSA became effective [. . .] our average payment by insurers of patient claims for emergency services has declined by approximately 30% including as much as a 37% reduction for physician services." The Company stated that, "[i]n our experience, insurers often initially pay amounts lower than the QPA without regard for other information relevant to the claim. This requires us to make appeals using the IDR process." 

In response, in July 2024, the Company engaged with HaloMD, a "third-party IDR vendor," to "assist in the recovery of certain out of network claims" in the IDR process. While Nutex did not disclose the identity of its third-party IDR vendor to investors at that time, the Company shortly thereafter began to tout the success of its "arbitration strategy" in increasing its revenues. For example, in August 2024, Nutex stated that it "believe[s] [] there is a lot of potential incremental value and revenue to be gained from arbitration" and "[i]n recent articles and public data, we are seeing that providers are prevailing 70% to 80% of the time in arbitration." Then, in March 2025, announcing its fourth quarter and full year 2024 results, Nutex reported that "[t]otal revenue increased $232.3 million to $479.9 million for the year ended December 31, 2024" and that "[t]he arbitration process resulted in approximately $169.7 million more in revenue in 2024 than in 2023, which amounted to approximately 73.1% of the $232.3 million revenue increase."

At all relevant times, the Company has identified material weaknesses in its internal control over financial reporting. Specifically, Nutex has acknowledged that it had "[i]neffective design, implementation, and operation controls over logical access, program change management, and vendor management controls," that "[b]usiness process controls across all financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer and key management review controls," and "[i]neffective design and implementation of controls over the completeness and accuracy of information included in key spreadsheets supporting the financial statements." However, Nutex has consistently represented that it has "started the process of designing and implementing effective internal control measures to remediate the reported material weaknesses."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 22, 2025, Blue Orca Capital ("Blue Orca") issued a short report on Nutex (the "Blue Orca Report" or the "Report"). The Blue Orca Report alleged, among other things, that "HaloMD achieved dramatically lucrative results for clients like Nutex by engaging in a coordinated fraudulent scheme to steal millions of dollars from insurance companies on behalf of and in conjunction with its healthcare billing clients." 

Specifically, Blue Orca referenced three recent "[b]ombshell [l]awsuits" filed against HaloMD. The lawsuits, brought variously by Blue Cross Blue Shield Healthcare Plan of Georgia, Inc., Community Insurance Company d/b/a Anthem Blue Cross and Blue Shield, and Anthem Blue Cross Life and Health Insurance Company and Blue Cross of California d/b/a Anthem Blue Cross, allege that HaloMD violated various federal and state laws by submitting false attestations of eligibility and initiating massive volumes of IDR disputes.

As summarized by Blue Orca, the plaintiffs in these lawsuits accused HaloMD and its clients of "flooding the arbitration system with thousands of claims that they knew at the time of submission to be ineligible" and alleging that HaloMD was able to garner improper payments by "falsely attesting to the eligibility of claims and [. . .] improperly inflating payment offers that far exceeded the amounts to which providers should have been entitled." Accordingly, Blue Orca concluded that "it may just be a matter of time before another suit is filed against HaloMD, this time including Nutex," and "[o]nce Nutex can no longer use the NSA arbitration system to receive unsustainably high reimbursement rates, our suspicion is that Nutex will return to penny stock status."

Following publication of the Blue Orca Report, Nutex's stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025.

On July 24, 2025, Nutex issued a press release responding to the Blue Orca Report, stating that it "strongly disagrees with the allegations in the report" and that it "expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025."

However, after the market closed on August 14, 2025, Nutex announced that it would "delay filing its Form 10-Q for the period ending June 30, 2025", citing "non-cash accounting adjustments related to the treatment of stock-based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings."

When Nutex failed to rebut the allegations of the Blue Orca Report, the Company's stock price fell $18.22 per share, or 16.39%, to close at $92.91 per share on August 15, 2025.

After the end of the Class Period, on August 21, 2025, Nutex filed a Current Report on Form 8-K with the SEC which, among other things, contained a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard and stated that the Audit Committee of the Company's Board of Directors concluded that certain of the Company's previously issued financial statements "treated non-cash obligations related to under-construction and ramping hospitals as equity rather than liabilities and should be restated." This filing also purported to address the Blue Orca Report. However, Nutex merely provided a generalized description of the arbitration process under the NSA and the Company's own claims process, acknowledged that Nutex had engaged HaloMD to assist in the IDR process, and discussed two of the three recent lawsuits filed against HaloMD, noting that the Company had not been named as a Defendant. As such, Nutex's filing did not in fact meaningfully rebut any of the allegations contained in the Blue Orca Report.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

HyperDrive DeFi protocol suffered a $773,000 exploit affecting two accounts in its Treasury Bill market with stolen funds split between BNB Chain and Ethereum networks through bridge transfers, as the attacker exploited an arbitrary call vulnerability in the router contract stealing 672,934 USDT0 and 110,244 thBILL tokens.

XRP Price at a Critical LevelThe $XRP Price is currently trading around $2.77, consolidating within a narrow range. With resistance at $3.00 and support at $2.70, the token is poised for a decisive move. According to recent XRP News, market sentiment remains cautious as traders await a breakout confirmation.

XRP Price in USD in the past week - TradingView 

This zone has become the battleground between bulls and bears, and the next breakout will likely dictate XRP’s direction in the coming weeks.

XRP Price Resistance at $3.00The $3.00 mark stands as the most important resistance level. It aligns with the 50-day simple moving average (SMA) at $2.96, making it a key barrier for buyers. A successful breakout above $3.00 would not only mark a technical victory for bulls but could also ignite fresh momentum toward $3.61 and $4.00.

XRP/USD 1-day chart - TradingView

In upcoming XRP News, a $3 breakout would be seen as the catalyst for the next bullish wave.

XRP Price Support at $2.70On the downside, $2.70 is the first major support. XRP has tested this level multiple times recently, and failure to hold it could push the token lower. The next key supports lie at $2.50 (200-day SMA) and $2.20. If the XRP Price slips below $2.70, market sentiment would likely turn bearish, with risks of a deeper correction toward the $2.00 mark.

XRP Price Prediction from a Technical OutlookSupport Levels: $2.70, $2.50, $2.20Resistance Levels: $3.00, $3.61, $4.00Trendlines & SMAs: The descending trendline from August caps rallies, while the 50-day and 200-day SMAs remain key momentum indicators.Currently, XRP is trapped between falling trendline resistance and horizontal support, a setup that typically leads to a sharp breakout in either direction.

XRP News and Market SentimentRecent XRP News has been mixed, with broader crypto volatility weighing on the token. However, optimism persists around potential regulatory clarity and institutional adoption, which could boost XRP’s outlook.

If Bitcoin stabilizes above its own critical supports, XRP may have a chance to ride the momentum higher. Conversely, continued weakness in the crypto market would make holding $2.70 increasingly difficult.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin’s global adoption numbers are about to explode, according to Jan3 founder Samson Mow.

Mow’s statement came during an interview with What Bitcoin Did’s Danny Knowles, where he said that the current cycle is behind schedule and that we should’ve had a bull run by now.

He also said that the current bear cycle could expand into 2026, but that, eventually, we’ll get a massive push, driven by institutional FOMO:

Mow believes that Bitcoin’s growth is inevitable and it’s all due to US’s pro-crypto legislation, with the GENIUS Act at the core of it.

Bitcoin Hyper ($HYPER) will also contribute to Bitcoin’s long-term success. As Bitcoin’s Layer 2 upgrade, Hyper promises faster and cheaper transactions, making the Bitcoin network more feasible for institutional investors.

Bitcoin Flatlines at $109K as Talks of Global Adoption Ramp Up
Bitcoin has been flatlined at little over $109K for three days now and it shows no signs of recovery.

However, the fact that the downward momentum stopped, following the brutal dip after the last FOMC meeting is already bullish.

This hints at a consolidation period, which will likely ramp up during Q4, especially with more nation-states ramping up their hoarding.

As Mow was declaring back in March 2023, every nation state should have at least 200,000 $BTC in their treasuries. The argument was that it’s unacceptable that Strategy, with its reserve of 132,500 Bitcoins, dwarfs nation-states.

The disparity has increased since then, with Strategy now holding 639,835 $BTC, valued at over $73B. According to data from Bitcoin Treasuries, this places it first on the list of companies with the largest Bitcoin reserves.

By comparison, the US currently holds 198,012 Bitcoins after selling 9,177 of them in December, 2024.

Fortunately, things are changing fast. A report by Fidelity Digital Assets titled ‘2025: Look Ahead’ stated that:

[…=] It may be too late for the speculators that want another frenzy. However, we believe we are still incredibly early in terms of this new era of sustainable adoption, diffusion, and integration.

—Fidelity Digital Assets, 2023: Look Ahead

With Bitcoin still far from reaching its true potential, we also need to look at Bitcoin Hyper ($HYPER) and how it promises to change the Bitcoin ecosystem.

How Bitcoin Hyper Lifts Bitcoin to New Performance Standards
Bitcoin Hyper ($HYPER) aims to solve Bitcoin’s performance limitation, currently at seven transactions per second (TPS), and remove the fee-based priority system, which sometimes raises confirmation times to hours.

In its quest for a faster and cheaper Bitcoin network, Hyper relies on tools like Solana Virtual Machine (SVM) and the Canonical Bridge to improve scalability, lower finality times to seconds, and eliminate network congestion.

The Canonical Bridge is at the core of it, connecting Hyper to the Bitcoin ecosystem and minting the users’ tokens into Hyper’s Layer 2. The wrapped Bitcoins are available for use on Layer 2 indefinitely, or until users decide to withdraw them to Bitcoin’s native layer.

Together with the Bitcoin Relay Program, which verifies and confirms incoming transactions near instantly, the Bridge makes the Bitcoin network more responsive and performant for faster and cheaper transactions.

This translates to sky-high scalability, which is the real prize. The increased scalability removes the fee-based priority system, which currently prioritizes larger and more fee-heavy transactions, with the smaller and cheaper ones often experiencing confirmation times of hours.

Long-term, Hyper plans to make Bitcoin a more feasible option for institutional investors and open the road to mainstream adoption.

The presale is growing fast, having raised over $18.6M so far with $HYPER valued at $0.012985.

Based on its utility and long-term roadmap, $HYPER could reach $0.32 by the end of the year. Our five-year price prediction for $HYPER is $1.50, given successful implementation and community support.

If you want to invest, learn how to buy $HYPER here, then go to the presale page and get your tokens today. Based on the presale numbers, we believe $HYPER to be the best crypto to buy in 2025.

This isn’t financial advice. Do your own research (DYOR) and invest wisely.

Authored by Patru Bogdan, Bitcoinist: https://bitcoinist.com/global-bitcoin-adoption-ramps-up-as-bitcoin-hyper-makes-big-gains

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Bitcoin adoption among countries worldwide is expected to enter a new phase after moving past the initial skepticism, according to Jan3 founder Samson Mow. Mow spoke on the What Bitcoin Did podcast hosted by Danny Knowles, giving insight into these issues and others connected to the leading digital asset.

During the podcast, Mow noted that we are towards the tail end when it comes to BTC adoption among countries.

“I think we’re on the tail end of gradually, and we’re at the beginning phases of suddenly,” Mow said.

Discussing the potential for more countries to follow that path, Mow noted that these things happen very quickly. “It’s like literally gradually then suddenly,” he said. He also added, “I think it is simply a matter of time before we see a massive run-up, and we see a massive nation-state FOMO, you know, panic.”

Bitcoin adoption could skyrocket among countries soon
In his statement, Mow mentioned that while United States President Donald Trump has signed an executive order to establish the country’s Strategic BTC Reserves, the US has yet to begin buying the asset. However, he added that the country is moving forward with budget-neutral Bitcoin acquisition and the Bitcoin Act. This means that the country will only acquire Bitcoin using existing assets and forfeited assets.

This stance was backed by Alex Thorn, Galaxy Digital’s head of firmwide research, noting that there is a high likelihood that the United States government will form the highly anticipated Strategic Bitcoin Reserve by the end of the year.

“I still think there’s a strong chance the US government will announce this year that it has formed the strategic Bitcoin reserve (SBR) and is formally holding BTC as a strategic asset,” Thorn said in an X post.

While the United States still leads other governments in total BTC holdings, Mow previously mentioned that the country needs to start purchasing new Bitcoin this year. He mentioned that it would be ironic and unfortunate for the United States and the Trump administration, which took bold steps to push this forward, to be front-run by other countries that are inspired by their actions. “The risk is that the US is front-run by Pakistan,” he explained.

Analysts expect a big Bitcoin push in 2026
Mow also said he anticipates a big BTC push from the Latin American region, noting that it is one of the areas that he is most bullish on. Bitcoin adoption among countries has been one of the most discussed topics since the beginning of the year. In a research paper released by Fidelity Digital Assets in January, it mentioned that more countries, sovereign wealth funds, central banks, and government treasuries will look to establish strategic positions in Bitcoin.

Meanwhile, Mow has mentioned that in terms of price, BTC has failed to perform as many experts and analysts predicted that it would in 2025. He added that, going by what they said before the start of the year, we should have already had a bull run, noting that they predicted a massive run-up before the start of the year. “So I think this cycle, if you want to call it a cycle, is delayed; it might push into next year,” he said.

The same sentiment has been echoed by other analysts and experts over the last few months. In July, Matt Hougan, Bitwise chief investment officer, mentioned that he feels 2026 is a bullish year for BTC. “I broadly think we’re in for a good few years,” Hougan said.

BTC is trading around $109,300, down by 1.9% over the past month, according to data from CoinMarketCap. The comments come amid debates about Bitcoin’s four-year cycle now that ETFs and institutional demand are present.

Get $50 free to trade crypto when you sign up to Bybit now

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Prominent market analyst with X username PlanD has shared an intriguing bullish projection of the Ethereum (ETH) market. Amid recent losses, which saw the ETH decline by 10.66% over the week, PlanD backs the altcoin market leader to reach a potential $21,000 price target by end of 2025.

Ethereum Ready For Surge As Triangle, Head & Shoulder Pattern Combines 
In an X post on September 27, PlanD provides a long-term price analysis of the Ethereum market, highlighting strong bullish potential. Over the last quarter, ETH has shown a strong price performance, breaking out of a four-year-long symmetrical triangle to establish a new all-time high at $4,953.

For context, the symmetrical triangle is a neutral chart pattern that forms when the price consolidates between two converging trendlines. When price breaks above the upper descending trendline, i.e., resistance as seen in the Ethereum market, it is usually interpreted as a bullish signal.

Source: @cryptododo7 on X
In line with the classic technical structure, PlanD further explains that the recent price decline over the past two weeks aligns with an expected retest of “this resistance” around $3,900. Having successfully bounced off this price zone, which now functions as a price floor, the analyst states that Ethereum has now resumed its uptrend, with the first major target being $5,900, which emerged from an inverse head and shoulders pattern (H&S)

The inverse head and shoulders is a bullish reversal chart pattern often seen after a downtrend. It signals that the market may be shifting from bearish to bullish momentum. This is clearly seen in the ETH price behavior so far in 2025. PlanD explains that if Ethereum successfully achieves the $5,900 inverse H&S target, the altcoin is expected to initiate a rally towards the symmetrical triangle formation’s major target of $21,000 by the end of 2025.

Ethereum Market Overview
At the time of writing, Ethereum is trading at $4,001 with almost no price change in the last day. However, market trading volume has dropped 58.67%, indicating weaker participation and declining short-term momentum.

According to blockchain analytics company Sentora, total network fees fell 3.9% week-on-week, suggesting reduced on-chain activity and lower demand for block space. Meanwhile, exchange netflows recorded –$3.08 billion week-on-week, meaning more Ethereum was withdrawn from exchanges than deposited, a generally bullish signal as it points to accumulation rather than selling pressure.

ETH trading at $3,997 on the daily chart | Source: ETHUSDT chart on Tradingview.com
Featured image from Pexels, chart from Tradingview

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Semilore Faleti works as a crypto-journalist at Bitconist, providing the latest updates on blockchain developments, crypto regulations, and the DeFi ecosystem. He is a strong crypto enthusiast passionate about covering the growing footprint of blockchain technology in the financial world.

The Pepe Coin price has crashed to a critical support level, indicating a potential for a steeper decline after forming a descending triangle, and whales initiate a selling spree.

Summary

Pepe Coin price has formed a descending triangle pattern on the daily chart.
On-chain data shows that whales have continued selling Pepe tokens.
Similarly, smart money investors are selling, while the supply in exchanges has jumped.

Pepe Coin price has formed a risky pattern
Pepe (PEPE), the second-biggest meme coin on Ethereum (ETH), plunged to a low of $0.000009155. That’s its lowest level since June 22 this year.

The meme coin plunged by over 45% from its highest point this year and by 68% from its 2024 highs.

The daily timeframe shows that the Pepe price dropped to a low of $0.000009017. This is a significant level, as it coincides with the lowest levels in June and September. 

A closer examination of this chart reveals that the coin’s pattern consists of a horizontal support and a descending trendline that connects the highest swings since May 22.

The profit target in a descending triangle pattern is established by first measuring the distance of the widest part and then the same distance from the triangle’s lower line. 

In this case, the distance is 45%, bringing the target price into $0.000004767. A crash to this level will be confirmed if it drops below the key support at $0.0000052.

Pepe price chart | Source: crypto.news
Whales are dumping Pepe tokens
On-chain data show that whale investors have continued to dump Pepe tokens this year. According to Nansen, whales now hold about 6.55 trillion tokens, their lowest holdings in months. 

They held over 7.6 trillion tokens on the same day in August this year. Similarly, smart money investors, who have a reputation for making profitable trades, have dumped their positions to 1.66 trillion. 

The ongoing dumping by these investors is having an impact on the exchange supply. There are now 253 trillion Pepe coins in exchanges, up from 252.4 trillion earlier this month. A jump in exchange supply is a signal that investors have given up on Pepe and are selling it.

Haider Rafique warns that a national Bitcoin reserve could unsettle markets and trigger significant downward pressure on Bitcoin prices.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Although Solana is often discussed in the same breath as Bitcoin and Ethereum, it hasn’t yet reached their level of mainstream investor interest or explosive price action.

That said, a recent development could very well put Solana next in line for its institutional moment.

ETF analyst Nate Geraci noted that a flurry of applications for Solana exchange-traded funds (ETFs) with staking were filed on Friday.

The applications came from some of the biggest names in the industry, including Franklin, CoinShares, Bitwise, Fidelity, Grayscale, Canary, and VanEck.

Most interestingly, Geraci pointed out that these ETFs could be approved within the next two weeks.

Read on as we unpack Solana’s brewing ETF momentum, what it could mean for the token and its price, and why buying Snorter Token ($SNORT) could be the best way to ride this rally.

ETF Approval: The Missing Catalyst for Solana
As mentioned earlier, Solana hasn’t yet unlocked the level of mainstream success that Bitcoin or Ethereum enjoy, and that could be a gap waiting to be filled.

Asset managers at Pantera Capital highlighted that ETF launches accelerated adoption of BTC and ETH, and the same could be the case with Solana.

Currently, Bitcoin has 43 ETFs and 165 public companies holding BTC, while Ethereum has 21 ETFs and 16 public companies holding ETH.

Compare this to Solana, which is still in its early days – there isn’t a comparable Solana ETF yet, and only 5 public companies currently hold SOL.

With institutions under-allocated to SOL relative to BTC and ETH, a Solana ETF approval could be the spark this token needs to realize its full potential.

Now here’s the kicker: investing directly into Solana is undoubtedly the most obvious way to benefit from the crypto’s bright future.

That said, in crypto, the success of these mainstream blockchains often ends up spurring the growth of related tokens.

With that in mind, Snorter Token ($SNORT), which is arguably the best Solana meme coin at the moment, stands to benefit the most from the crypto’s upcoming rally.

Snorter is a trading bot currently in development that aims to give meme coin traders the ultimate tool to go toe-to-toe with the institutional players who currently dominate the space.

Snorter Is Changing the Meme Coin Trading Space
What is Snorter Token? $SNORT is the native cryptocurrency of the Snorter Telegram Bot, which stands out thanks to its sub-second swiping and rock-solid security infrastructure.

For starters, it lets you place buy and sell, limit, and stop orders well before liquidity kicks in for a new meme coin.

And when it finally does, it automatically executes those orders almost instantaneously. This allows you, a retail participant, to finally ride those initial meme coin pumps, which are easily the most profitable.

Consider why this is game-changing: up until now, institutional players with advanced tools and algorithms ate up all the liquidity, and therefore all the profits, leaving nothing for the average person.

Snorter changes this game and finally brings parity to the meme coin market, which has grown over 25% in just the last year and could arguably be the biggest beneficiary of crypto’s expanding footprint.

This is also why, according to our Snorter Token price prediction, the token could reach $0.94 by the end of 2025.

That means if you invest $100 into the token right now – while it’s in presale and available at super low prices – you could potentially walk away with $900 in just a few months.

Snorter Offers Top-Notch Security & Ease of Use
Snorter’s security is a thing of beauty. It’s laced with features to protect you against all big and small on-chain threats, from front-running and rug pulls to honeypots and even sophisticated sandwich attacks.

On top of that, it’s also one of the easiest-to-use trading bots available right now.

Since it’s based on Telegram, all you have to do to place your orders is send commands (which are essentially messages) in the familiar Telegram chat interface.

It’s also worth noting that Snorter comes with a handy copy-trading feature.

As the name suggests, it lets you connect your wallet to that of seasoned blockchain traders, meaning every trade they take will also be mimicked on your own account, without you having to lift a finger.

This allows you to make some decent profits in a hands-off manner. That said, it’s very important to choose the right expert to copy-trade your account.

We also suggest thinking of this feature as a form of guidance – something to help you learn – before you begin trading independently.

Buy $SNORT Now for Maximum Gains
Buying Snorter Token would give you front-row seats to the bot’s growth, which has all the potential to follow an explosive curve, given the growing legitimacy around meme coins and the number of people now viewing them as serious trading instruments.

Even better, if you’re a $SNORT holder, you’ll unlock exclusive benefits while using the trading bot. These include:

No daily sniping limits
Access to advanced analytics
Reduced trading fees of just 0.85% (compared to 1.5% charged to non-holders)
Staking rewards currently yielding 114%

This new cryptocurrency project is currently in presale, having already raised over $4.1M from early investors.

Arguably the best part is that each token is still available for just $0.1063. Interested? Here’s our detailed guide on how to buy Snorter Token.

Visit Snorter Token’s official website to learn more about its benefits, roadmap, and tokenomics.

Disclaimer: Crypto investments are highly risky. None of the above constitutes financial advice, so kindly do your own research before investing.

Authored by Krishi Chowdhary, Bitcoinist – https://bitcoinist.com/solana-staking-etfs-approval-in-2-weeks-why-snort-biggest-beneficiary

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Sellers keep controlling the initiative on the last day of the week, according to CoinMarketCap.

Top coins by CoinMarketCapDOGE/USDThe price of DOGE has fallen by 1.63% over the last day.

Image by TradingViewOn the hourly chart, the rate of DOGE is returning to the local support of $0.2258. If a breakout happens, the decline is likely to continue to the $0.2250 zone by tomorrow.

Image by TradingViewOn the bigger time frame, the situation is similar.

You Might Also Like

The rate of DOGE is closer to the support than to the resistance level. If buyers cannot seize the initiative, traders may witness a breakout, followed by an ongoing drop to the $0.21-$0.2150 range.

Image by TradingViewFrom the midterm point of view, the price of the meme coin keeps going down after a false breakout of the resistance of $0.2929. If the weekly bar closes with a short wick, there is a high chance of a test of the $0.20 zone soon.

DOGE is trading at $0.2261 at press time.

TLDR:

Skynet uses Sui’s fast blockchain to run AI agents that process payments and data without central control.
Developers can deploy user-specific AI agents with strong privacy protections on Sui’s scalable network.
The platform links Web2 APIs like Stripe or AWS to blockchain-based AI, bridging old and new systems.
Skynet is described as a nervous system for decentralized AI, enabling autonomous actions in real time.

Decentralized AI is taking a new step forward with Skynet’s integration on the Sui blockchain. The project introduces a system where AI agents can act independently, interact with real-world services, and even process payments without middlemen. 

Its builders describe it as an open, collaborative network that connects digital intelligence with real-world tools. This approach promises faster execution and secure data handling. Crypto investors are watching closely as new infrastructure like this gains traction.

How Skynet Works on the Sui Blockchain
MartyParty, a crypto analyst, shared that Skynet is being built as a dual-platform system on Sui. 

The first layer lets developers deploy AI agents that can act in the real world. These agents could run trades, control connected devices, or handle logistics workflows without a centralized gatekeeper.

Skynet on Sui: The Next-Gen Decentralized AI Infrastructure

Based on recent developments in the crypto and AI space, "Skynet SUI" refers to a decentralized AI agent platform being built on the @SuiNetwork blockchain (native token: $SUI). It's a collaborative, permissionless… https://t.co/KRht5DVTh6

— MartyParty (@martypartymusic) September 28, 2025

The second layer focuses on compatibility with existing Web2 services. It translates APIs from platforms such as Stripe or AWS so that AI agents can use them directly. This means agents could handle billing or cloud data access without exposing private credentials.

Privacy remains central to the system’s design. Developers can spin up agents per user, isolating sensitive data from outside parties. This design also enables scalability since every user gets a private environment without slowing down the network.

Sui’s architecture supports these operations with low-latency execution and parallel processing. This is key for AI agents that need to act quickly in live scenarios like financial markets or connected devices.

Why Sui’s Speed Matters for AI
Sui Network is known for its high throughput and horizontal scaling. This makes it well-suited for workloads where speed and security must work together. MartyParty noted that this is what makes Sui an ideal home for Skynet’s infrastructure.

Low-latency means agents can respond to events almost instantly. That matters for use cases like algorithmic trading, where milliseconds can impact price execution. It also matters for IoT or robotics use cases where real-time feedback loops are critical.

Parallel processing lets multiple AI agents run at the same time without creating network congestion. This could open the door for thousands of independent agents working across finance, logistics, and Web3 gaming simultaneously.

For crypto developers, this setup means they can build and scale without rewriting their entire stack. It lowers friction for onboarding new AI-driven dApps and services.

Sun, 28/09/2025 - 12:44

XRP set for 16% breakout against Bitcoin, Bollinger Bands signal

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Following an explosive rally of 320% at the beginning of the year, it seemed that XRP's outperformance of Bitcoin had come to an end. Currently, one XRP token is estimated to be worth 0.00002541 BTC, which is 25.81% below its peak value.

For many, this marked the end, but Bollinger Bands support the opposite thesis — and they do so on the weekly timescale. XRP has just defended its mid-band versus Bitcoin on the weekly chart, making the scenario of testing the higher band at 0.000026 BTC more probable for now.

This would be 16% higher than the current price.

HOT Stories

XRP/BTC on Binance by TradingViewIt is all about chart mechanics. When a pair holds the weekly mid-band, it signals not collapse but the possibility of reaching the top band. That's what's on the table now: 0.000026 as the next target price.

Had the defense failed, the conversation would already be about 0.000021, but it didn’t. The ratio stayed alive.

XRP, Bitcoin and dollarIn the meantime, Bitcoin is trading at six-figure prices and Ethereum is holding at around $4,000. However, none of this explains why XRP at $2.78 is such a big deal. The ratio does.

Traders who only look at the dollar chart miss the fact that XRP has a clean 16% gap above it before resistance even shows up. The whole play is this: The mid-band held, the upper band is in sight.

If XRP/BTC breaks into that zone, it won't just be a random candle. It will be the first serious confirmation in months that this pair is alive and well. The weekly bands are already pointing the way.

Related articles

Key NotesCathie Wood compared Hyperliquid to Solana’s early breakout years.VanEck CEO Jan van Eck praised HYPE’s technology and governance.HYPE trades 26% below its ATH, with $40–41 acting as key support.
ARK Invest CEO Cathie Wood compared decentralized perpetuals exchange Hyperliquid to Solana’s early breakout years, calling it “the new kid on the block.”

While speaking on the Master Investor podcast, Wood called Hyperliquid “exciting,” adding that the DEX reminds her of Solana in the earlier days.

“Solana has proven its worth and is, you know, there with the big boys,” Wood said, revealing that ARK currently focuses its crypto exposure on Bitcoin, Ethereum, and Solana.

She sees the rise of decentralized exchanges (DEXs) reshaping trading infrastructure in the near future.

Institutional Endorsements Fuel Momentum
Hyperliquid has also caught the attention of traditional finance heavyweights. Earlier this month, VanEck CEO Jan van Eck praised the Layer 1 blockchain’s “advanced technology and decentralized governance.”

He confirmed that VanEck has an active role in ecosystem governance and research for Hyperliquid. The asset manager hinted at future partnerships, showing significant demand for DEX infrastructures.

Hype Price Analysis: Chart Analysis
HYPE reached an all-time high of $59.39 earlier in September but has since corrected to $43.77, marking a 26% pullback.

The daily chart shows the token breaking below its rising wedge pattern, a typically bearish signal, with price now testing the lower Bollinger Band near $40.65.

Meanwhile, the RSI sits at 41.55, leaning toward oversold conditions but not yet signaling reversal strength. The MACD shows bearish momentum, while the Chaikin Money Flow (CMF) has dipped into negative territory, suggesting outflows.

HYPE daily chart breaking down from rising wedge | Source: TradingView

Interestingly, if HYPE can reclaim the $45–47 range and flip $51.36 (20-day moving average) into support, upside targets include the $55 level and a potential retest of the all-time high at $59.39.

A breakout above that resistance zone could open the door toward $62–70 in the medium term.

Failure to hold the $40–41 support zone risks deeper losses. A breakdown below $40 could expose $35, with further downside toward $30 if bearish momentum accelerates.

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Altcoin News, Cryptocurrency News, News

A crypto journalist with over 5 years of experience in the industry, Parth has worked with major media outlets in the crypto and finance world, gathering experience and expertise in the space after surviving bear and bull markets over the years. Parth is also an author of 4 self-published books.

Parth Dubey on LinkedIn

The SPDR Portfolio S&P 500 High Dividend ETF should top the list for dividend-seeking investors.

Earning income from your investments can prove fruitful in building wealth. And you don't have to start with a lot of money to receive passive income; you can start small and build up your positions over time.

With the Federal Reserve recently cutting short-term interest rates and indicating further reductions are due over the next couple of years, getting high interest rates from vehicles like savings accounts has become more challenging.

Given the lower-rate environment, dividends from stocks should play a larger role in your passive-income portfolio. You can accomplish this with exchange-traded funds (ETFs). Investing in a portfolio of equities allows you to achieve diversification, while ETFs also provide the liquidity of a stock since they trade throughout the day.

However, you shouldn't get fooled into thinking that you'll have no work to do. You still have to choose the right ETF. Given the current interest rate environment and potential for volatile market conditions, the SPDR Portfolio S&P 500 High Dividend ETF (SPYD 0.91%) should top your list of candidates if you're looking for passive income.

Image source: Getty Images.

What does the ETF invest in?
The SPDR Portfolio S&P 500 High Dividend ETF tracks the S&P 500 High Dividend Index, which consists of 80 stocks with high yields. Interestingly, the index assigns equal weight to each stock rather than weighting by market capitalization.

The ETF has its largest investment in the real estate sector, with a 22.4% allocation. Other major sector allocations include consumer staples (16.7%), financials (15.5%), utilities (12.9%), and heathcare (8%).

By comparison, the SPDR S&P 500 ETF Trust, which tracks the S&P 500, has a very different sector allocation. The portfolio has the largest amount invested in the information technology sector at 34.6%. That's followed by financials (13.6%), consumer discretionary (10.5%), communication services (10.4%), and healthcare (8.8%).

As you might expect, the differing sector weighting results in different yields. The SPDR S&P 500 High Dividend ETF has a 4.7% yield, while the SPDR S&P 500 ETF Trust yields 1.1%.

A low fee structure
The SPDR Portfolio S&P 500 High Dividend ETF invests passively. That means it can charge low fees since it doesn't have to pay a lot of money to run the fund, including to portfolio managers.

The ETF has an expense ratio of 0.07%. That's how much it costs to run the fund, and it reduces your return. All else equal, the lower the expense ratio, the better the return to investors.

A 0.07% expense ratio means that for every $100 invested, the fund subtracts just seven cents. That's even better than many equity index ETFs, which had an average expense ratio of 0.14% in 2024, according to the Investment Company Institute.

Risk and return
Over the last five years through Aug. 31, the SPDR Portfolio S&P 500 High Dividend ETF returned an annualized 14.8%. By comparison, the S&P 500 ETF produced a 14.6% return during this time.

However, the underlying S&P 500 High Yield Index had higher volatility at 18.2%, versus 16% for the S&P 500. Hence, during this period, the latter produced a better risk-adjusted return, as measured by the Sharpe ratio.

But given each index's composition, the falling interest rate environment, and the SPDR Portfolio S&P 500 High Dividend ETF's focus on dividend-paying stocks, it looks poised to produce strong returns and lower volatility compared to the S&P 500.

Lawrence Rothman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

These stocks have reacted to AI in surprising ways, but investors should also consider their future prospects.

As tech investors have observed, artificial intelligence (AI) propelled many stocks higher since the release of OpenAI's GPT-4. Thanks to the gains sparked by this technology, several individual stocks and the stock indexes reached record highs in recent trading sessions.

This has to many AI stocks setting new all-time highs. Also, Grand View Research forecasts a 32% compound annual growth rate (CAGR) in the AI sector through 2033, leading to questions about what comes next, especially for individual stocks in this sector. With that question in mind, three analysts from The Motley Fool share their insights on some of the most critical AI stocks and where they are likely to go from here.

Image source: Getty Images.

1. Nvidia will likely exceed $200 billion in sales this fiscal year
Jake Lerch (Nvidia): My choice is Nvidia (NVDA 0.27%). There's no doubt in my mind that Nvidia -- more than any other company -- has been the prime beneficiary of the AI revolution. After all, this is a company that, in just a few years, has risen to become the largest company by market capitalization in the world.

So, what are investors to make of Nvidia? What is the ceiling for the company? Or is there no ceiling at all?

Obviously, the answers to these questions revolve around the AI ecosystem and Nvidia's prime role within it. If the AI revolution continues to roll on, so will Nvidia. If AI investment slows or collapses, Nvidia's stock will tumble. Moreover, what if new competitors challenge Nvidia's enormous lead within the graphics processing unit (GPU) market?

First, there are legitimate concerns about the amount of spending on AI infrastructure -- and what return on investment (ROI) companies will get from it. Meta Platforms, Tesla, Microsoft, Amazon, Alphabet, and many others are investing billions in AI infrastructure -- much of it in the form of Nvidia's advanced GPUs. These companies each have their own unique vision for utilizing their AI resources and their own ROI expectations.

For the moment, there is no sign that their ROI isn't measuring up. Indeed, the escalating scale of the investments suggests that ROIs are even better than expected.

Second, it's true that competitors will eventually close the gap on Nvidia. That is the nature of capitalism. However, the question remains how long that process will take to play out. According to estimates compiled by Yahoo! Finance, Nvidia is expected to generate $206 billion in revenue for the fiscal year (the 12 months ending Jan. 27, 2026), and nearly $275 billion in the following 12 months.

So, competition will eventually emerge. Still, it is not expected to substantially impact Nvidia's growth over the next 18 months.

Nvidia remains the top dog in both the AI sector and the broader stock market. Overall, AI investment remains robust, suggesting that companies are reaping substantial benefits from their AI spending. Finally, Nvidia's competitors remain years off from fully challenging the company's strong sales growth. In short, Nvidia remains an AI stock superstar.

2. Investors must weigh company gains against stock growth in this stock
Will Healy (Palantir): Palantir Technologies (PLTR -0.83%) has been an AI company since its inception. The technology played a critical role in delivering analytical insights in the national security and commercial sectors.

More recently, the launch of its generative AI-based Artificial Intelligence Platform (AIP) undoubtedly supercharged these capabilities. Numerous customers from diverse enterprises reported eye-popping productivity gains. Amid such improvements, Palantir's stock is up by nearly 370% over the last year.

Unfortunately for bulls in this stock, its financials call into question the near-term direction of Palantir stock. In the first half of 2025, Palantir earned a net income attributable to common shareholders of $541 million, a 126% yearly gain.

While that is an impressive amount of growth by any measure, it fell short of the gains in the stock price. Consequently, Palantir reached stratospheric valuations. Even if investors can dismiss the 592 P/E ratio, its price-to-sales (P/S) ratio of 131 is far removed from the S&P 500's average sales multiple of 3.4.

Does this mean Palantir's stock is headed for a crash, or at least a pause? Not necessarily, as it is always possible that it will beat expectations or find some other factor that will propel the stock higher.

The problem with these valuations is that they price Palantir stock for perfection. That means any hint of negative news could trigger a massive sell-off, making it extremely risky to buy the stock at current prices.

Amid that possibility, investors should probably refrain from putting new money to work in Palantir. Additionally, if one's risk tolerance does not lend itself to owning such an expensive stock, they should consider selling.

3. Don't write off Apple as an AI powerhouse just yet
Justin Pope (Apple): Iconic electronics titan Apple (AAPL -0.57%) has faced considerable criticism for its lackluster rollout of AI iOS features it had dubbed Apple Intelligence.

It was supposed to be an easy layup -- there are over 2.35 billion active iOS devices worldwide. Successfully bringing AI to Apple users would have almost assured the company's place as a top AI company, where next-generation technology would further enhance its already sticky ecosystem.

Unfortunately, Apple dropped the ball. The company has struggled to ship first-party AI features and has since delayed its launch of an upgraded Siri, Apple's virtual personal assistant, to a 2026 release date. But don't write Apple off just yet. The company continues to specialize in bringing refined, quality hardware products to market, allowing its iOS ecosystem to shine.

Apple just launched its latest iPhone models: the 17, 17 Pro, and Pro Max, as well as a new, slim-design model, the iPhone Air. According to early indications, Apple may be in for a strong hardware cycle. The CEO of T-Mobile recently noted that iPhone sales are at an all-time high. Industry experts also pointed out strong demand for the new iPhone lineup.

While Apple must ultimately deliver a working and compelling slate of AI features for its devices, it's clear that Apple's core hardware products haven't lost their fastball. That should give the company time to figure out AI and keep the stock on the radar of any investor looking for some AI upside, but would rather stick with a blue-chip winner versus rolling the dice on unproven or speculative AI stocks.

Jake Lerch has positions in Alphabet, Amazon, Nvidia, and Tesla. Justin Pope has no position in any of the stocks mentioned. Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Palantir Technologies, and Tesla. The Motley Fool recommends T-Mobile US and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.